Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LTBR-mediated immunomodulation of the tumor microenvironment promotes anti-tumor responses

ABSTRACT: LTBR-mediated immunomodulation of the tumor microenvironment promotes anti-tumor responses

PROVIDER: PRJNA1016471 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26057800.fastq.gz	Fastqsanger.gz
	SRR26057801.fastq.gz	Fastqsanger.gz
	SRR26057802.fastq.gz	Fastqsanger.gz
	SRR26057803.fastq.gz	Fastqsanger.gz
	SRR26057804.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 116

Similar Datasets

LTBR-mediated immunomodulation of the tumor microenvironment promotes anti-tumor responses

Project description:The presence of high endothelial venules (HEV) and tertiary lymphoid structures (TLS) in solid tumors is correlated with favorable prognosis in many cancer types and has been associated with better treatment responses to immune-checkpoint blockade (ICB). However, the molecular mechanisms underlying intratumoral HEV and TLS formation and their contribution to anti-tumor responses remain unclear. Lymphotoxin beta receptor (LTBR) signaling is a critical regulator of lymph node organogenesis and when combined with antiangiogenic and ICB treatment can augment tumor-associated HEV formation. Here we demonstrate that LTBR signaling modulates the tumor microenvironment via multiple mechanisms to promote anti-tumor T cell responses. Systemic activation of the LTBR pathway via agonistic antibody treatment induced tumor-specific HEV formation, upregulated the expression of TLS-related chemokines, and enhanced dendritic cell (DC) and T cell infiltration and activation in syngeneic tumor models. In vitro studies confirmed direct effects of LTBR agonism on DC activation and maturation and associated DC- mediated T cell activation. Single agent LTBR agonist treatment inhibited syngeneic tumor growth in a CD8+ T cell- and HEV-dependent manner; and the LTBR agonist enhanced anti-tumor effects of anti-PD-1 and CAR T cell therapies, respectively. An in vivo tumor screen for TLS-inducing cytokines revealed that the combination of LTBR agonism and lymphotoxin alpha (LT⍺) expression promoted robust intratumoral TLS induction and enhanced tumor responses to anti-CTLA-4 treatment. Collectively, this study highlights crucial functions of LTBR signaling in modulating the tumor microenvironment and inform future HEV/TLS- based strategies for cancer treatments.

2024-08-08 | GSE243170 | GEO

Senescence rewires microenvironment sensing to facilitate anti-tumor immunity

Project description:Senescence rewires microenvironment sensing to facilitate anti-tumor immunity

| PRJNA928706 | ENA

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer

Project description:Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer

| PRJNA1003471 | ENA

Senescence rewires microenvironment sensing to facilitate anti-tumor immunity (scRNA-Seq)

Project description:Senescence rewires microenvironment sensing to facilitate anti-tumor immunity (scRNA-Seq)

| PRJNA928712 | ENA

Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming

Project description:Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming

| PRJNA978069 | ENA

Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity

Project description:Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity

| PRJNA832275 | ENA

Pro- and anti-tumorigenic capacity of immunoproteasomes in shaping the tumor microenvironment

Project description:Pro- and anti-tumorigenic capacity of immunoproteasomes in shaping the tumor microenvironment

| PRJNA634311 | ENA

Senescence rewires microenvironment sensing to facilitate anti-tumor immunity (bulk RNA-Seq)

Project description:Senescence rewires microenvironment sensing to facilitate anti-tumor immunity (bulk RNA-Seq)

| PRJNA838824 | ENA

The role of residue chirality of polypeptide hydrogels in regulating local immune microenvironment for anti-tumor immune responses

Project description:The impact of chirality on immune response has attracted great interest in cancer vaccine research recently. However, the study of chiral synthetic polypeptide hydrogels as cancer vaccines as well as of the impact of biomaterials itself for antitumor immunotherapy has rarely been reported. Herein, we demonstrated the key role of residue chirality of polypeptides hydrogels in antitumor immunity and local immune microenvironment regulation. Compared to poly(γ-ethyl-L-glutamate)-based hydrogels (L-Gel), poly(γ-ethyl-D-glutamate)-based hydrogels (D-Gel) induced greater immune cell infiltration. Unexpectedly, D-Gel caused higher levels of suppressive markers on antigen-presenting cells and even induced stronger T cells exhaustion than L-Gel. Finally, D-Gel established a local chronic inflamed and immunosuppressive microenvironment and showed insufficient anti-tumor effects. Conversely, the milder host immune responses induced by L-Gel led to more effective tumor inhibition. This study provides new insights on the role of residue chirality in the regulation of local immune microenvironment and affecting antitumor immune response.

2024-03-14 | GSE261299 | GEO

Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer [scRNA-seq2]

Project description:Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer [scRNA-seq2]

| PRJNA1141962 | ENA